<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Drug Alcohol Depend</journal-id><journal-id journal-id-type="iso-abbrev">Drug Alcohol Depend</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Drug and alcohol dependence</journal-title></journal-title-group><issn pub-type="ppub">0376-8716</issn><issn pub-type="epub">1879-0046</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10940194</article-id><article-id pub-id-type="pmcid-ver">PMC10940194.319</article-id><article-id pub-id-type="pmcaid">10940194</article-id><article-id pub-id-type="pmcaiid">10940194</article-id><article-id pub-id-type="manuscript-id">NIHMS1966667</article-id><article-id pub-id-type="pmid">38335797</article-id><article-id pub-id-type="doi">10.1016/j.drugalcdep.2024.111112</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1966667</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1966667</article-id><article-version article-version-type="pmc-version">319</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Estimated Effectiveness and Cost-Effectiveness of Opioid Use Disorder Treatment Under Proposed U.S. Regulatory Relaxations: A Model-Based Analysis</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Qian</surname><given-names initials="G">Gary</given-names></name><degrees>MS</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Humphreys</surname><given-names initials="K">Keith</given-names></name><degrees>PhD</degrees><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Goldhaber-Fiebert</surname><given-names initials="JD">Jeremy D.</given-names></name><degrees>PhD</degrees><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Brandeau</surname><given-names initials="ML">Margaret L.</given-names></name><degrees>PhD</degrees><xref rid="A1" ref-type="aff">1</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Management Science and Engineering, Stanford University, Stanford, CA</aff><aff id="A2"><label>2</label>Center for Innovation to Implementation, VA Palo Alto Health Care System, Palo Alto, CA</aff><aff id="A3"><label>3</label>Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA</aff><aff id="A4"><label>4</label>Department of Health Policy, Stanford University, Stanford, CA</aff><author-notes><corresp id="CR1"><bold>Corresponding Author:</bold> Gary Qian, Department of Management Science and Engineering, Huang Engineering Center, 475 Via Ortega, Stanford University, Stanford, CA 94305-4026, Phone: 650-935-1790, <email>gqia189@stanford.edu</email></corresp><fn fn-type="con" id="FN1"><p id="P1">Contributors</p><p id="P2">GQ, KH, JDG, and MB made substantial contributions to the study conception and design. GQ, and MB made substantial contributions to the literature search and the curation of data. GQ conducted the formal analysis and produced the figures. MB drafted the first version of the manuscript. GQ, KH, JDG, and MB contributed to critical revisions and approved the final version of the manuscript. KH and MB obtained study funding.</p></fn><fn fn-type="COI-statement" id="FN3"><p id="P51"><bold>Declaration of interests:</bold> None to declare</p></fn><fn fn-type="COI-statement" id="FN4"><p id="P52">Conflict of Interest</p><p id="P53">The authors have no conflicts of interest to declare.</p></fn></author-notes><pub-date pub-type="ppub"><day>01</day><month>3</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>01</day><month>2</month><year>2024</year></pub-date><volume>256</volume><issue-id pub-id-type="pmc-issue-id">457926</issue-id><fpage>111112</fpage><lpage>111112</lpage><pub-history><event event-type="nihms-submitted"><date><day>15</day><month>02</month><year>2024</year></date></event><event event-type="pmc-release"><date><day>01</day><month>03</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>01</day><month>03</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-04-04 15:25:35.543"><day>04</day><month>04</month><year>2025</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1966667.pdf"/><abstract id="ABS1"><sec id="S1"><title>Aim:</title><p id="P3">To assess the effectiveness and cost-effectiveness of buprenorphine and methadone treatment in the U.S. if exemptions expanding coverage for substance use disorder services via telehealth and allowing opioid treatment programs to supply a greater number of take-home doses of medications for opioid use disorder (OUD) continue (Notice of Proposed Rule Making, NPRM).</p></sec><sec id="S2"><title>Design, Setting and Participants:</title><p id="P4">Model-based analysis of buprenorphine and methadone treatment for a cohort of 100,000 individuals with OUD, varying treatment retention and overdose risk among individuals receiving and not receiving methadone treatment compared to the status quo (no NPRM).</p></sec><sec id="S3"><title>Intervention:</title><p id="P5">Buprenorphine and methadone treatment under NPRM.</p></sec><sec id="S4"><title>Measurements:</title><p id="P6">Fatal and nonfatal overdoses and deaths over five years, discounted lifetime per person QALYs and costs.</p></sec><sec id="S5"><title>Findings:</title><p id="P7">For buprenorphine treatment under the status quo, 1.21 QALYs are gained at a cost of $19,200/QALY gained compared to no treatment; with 20% higher treatment retention, 1.28 QALYs are gained at a cost of $17,900/QALY gained compared to no treatment, and the strategy dominates the status quo. For methadone treatment under the status quo, 1.11 QALYs are gained at a cost of $17,900/QALY gained compared to no treatment. In all scenarios, methadone provision cost less than $20,000/QALY gained compared to no treatment, and less than $50,000/QALY gained compared to status quo methadone treatment.</p></sec><sec id="S6"><title>Conclusions:</title><p id="P8">Buprenorphine and methadone OUD treatment under NPRM are likely to be effective and cost-effective. Increases in overdose risk with take-home methadone would reduce health benefits. Clinical and technological strategies could mitigate this risk.</p></sec></abstract><kwd-group><kwd>Cost-effectiveness analysis</kwd><kwd>Opioid use disorder</kwd><kwd>Buprenorphine treatment</kwd><kwd>Methadone treatment</kwd><kwd>Simulation</kwd><kwd>Dynamic compartmental model</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>